GALPHARM INTERNATIONAL LIMITED
Get an alert when GALPHARM INTERNATIONAL LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2027-04-06 (in 11mo)
Last made up 2026-03-23
Watchouts
Cash
£323K
-37.9% vs 2023
Net assets
£23K
-99.9% vs 2023
Employees
35
-58.8% vs 2023
Profit before tax
£6M
+4% vs 2023
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Material uncertainty over going concern
The financial statements therefore have not been prepared on a going concern basis. Instead, they have been prepared on a break-up basis reflecting the imminent liquidation and closure of the company.
Name history
Renamed 1 time since incorporation
- GALPHARM INTERNATIONAL LIMITED 1995-12-22 → present
- GAL PHARM INTERNATIONAL LIMITED 1981-02-24 → 1995-12-22
Net assets
2-year trend · vs Consumer Discretionary median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £123,079,000 | £57,374,000 | |
| Operating profit | £5,756,000 | £4,278,000 | |
| Profit before tax | £5,447,000 | £5,664,000 | |
| Net profit | £4,152,000 | £4,388,000 | |
| Cash | £520,000 | £323,000 | |
| Total assets less current liabilities | £34,128,000 | £23,000 | |
| Net assets | £34,128,000 | £23,000 | |
| Equity | £34,128,000 | £23,000 | |
| Average employees | 85 | 35 | |
| Wages | £3,322,000 | £1,506,000 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 4.7% | 7.5% | |
| Net margin | 3.4% | 7.6% | |
| Return on capital employed | 16.9% | 18600.0% | |
| Current ratio | 2.38x | 1.08x | |
| Interest cover | 6.30x | 12.51x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Audit opinion
- Unaudited (audit-exempt)
- Going concern
- Material uncertainty disclosed
“The financial statements therefore have not been prepared on a going concern basis. Instead, they have been prepared on a break-up basis reflecting the imminent liquidation and closure of the company.”
Significant events
- “On 19th January 2024 the directors announced their intention to combine the UK Storebrand (Galpharm International) and Branded (Omega Pharma) business on 3 June 2024.”
- “Although the trade of the business has continued uninterrupted and has just be transferred to another Perrigo owned company under the same leadership team, it is recognised by the directors for the purpose of Statutory reporting that Galpharm International Ltd did cease to trade after 3rd June 2024 and the director's intention is to liquidate the Company within 12 months of signing these financial statements.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 21 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| LORDEN, Bradley | Secretary | 2025-02-21 | — | — |
| DOHERTY, Sarah Jane | Director | 2025-02-03 | Feb 1984 | British |
| RUDD, Christopher Allan | Director | 2018-04-03 | Sep 1980 | British |
Show 21 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| CORCORAN, Annette | Secretary | 2017-05-25 | 2025-02-21 |
| HEWERDINE, Mark | Secretary | 1998-08-01 | 2008-01-09 |
| HOYLE, Melvyn | Secretary | 1996-03-31 | 1998-07-31 |
| KAVANAGH, Niall Patrick | Secretary | 2014-05-27 | 2017-05-25 |
| LESLIE, Craig Andrew | Secretary | 1995-01-11 | 1996-03-31 |
| LESLIE, Graham Andrew, Dr | Secretary | — | 1995-01-11 |
| TUCKER, Michael Andrew | Secretary | 2008-01-09 | 2014-05-27 |
| BRASS, Andrew Ronald | Director | — | 1993-05-04 |
| COX, Peter Noel Miller | Director | 1997-04-11 | 1999-12-31 |
| DOSE, Sheenagh | Director | 2018-04-03 | 2018-07-11 |
| HOLME, Richard | Director | 2023-01-03 | 2024-03-31 |
| HOWARD, Russell Peter | Director | 2008-01-09 | 2016-02-05 |
| LESLIE, Anne Rachel | Director | — | 1995-06-19 |
| LESLIE, Craig Andrew | Director | 1992-09-01 | 2008-01-09 |
| LESLIE, Graham Andrew, Dr | Director | — | 2008-01-09 |
| LISTER, Neil Thomas | Director | 2016-02-05 | 2023-01-03 |
| MILLS, Stuart Charles | Director | 2024-03-31 | 2025-08-31 |
| O'SULLIVAN, Patrick Michael | Director | 2014-03-18 | 2018-04-03 |
| RIVERS, Dominic James | Director | 2018-04-03 | 2025-02-03 |
| THOMPSON, Philip | Director | 2017-09-01 | 2018-04-03 |
| TUCKER, Michael Andrew | Director | 2008-01-09 | 2016-10-31 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Galpharm Healthcare Limited | Corporate entity | Shares 75–100% | 2016-04-06 | Active |
Filing timeline
Last 20 of 163 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-04-24 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2026-04-15 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-01-22 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2025-10-09 | AA | accounts | Accounts with accounts type full | |
| 2025-09-02 | TM01 | officers | Termination director company with name termination date | |
| 2025-05-15 | CH01 | officers | Change person director company with change date | |
| 2025-04-03 | TM01 | officers | Termination director company with name termination date | |
| 2025-03-23 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-03-07 | AP03 | officers | Appoint person secretary company with name date | |
| 2025-03-07 | TM02 | officers | Termination secretary company with name termination date | |
| 2025-02-21 | AP01 | officers | Appoint person director company with name date | |
| 2024-09-11 | AA | accounts | Accounts with accounts type full | |
| 2024-04-15 | AP01 | officers | Appoint person director company with name date | |
| 2024-04-12 | TM01 | officers | Termination director company with name termination date | |
| 2024-03-25 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-05-24 | AA | accounts | Accounts with accounts type full | |
| 2023-03-27 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-01-10 | AP01 | officers | Appoint person director company with name date | |
| 2023-01-10 | TM01 | officers | Termination director company with name termination date | |
| 2022-06-23 | AA | accounts | Accounts with accounts type full |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 6
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
-53.4%
£123,079,000 £57,374,000
-
Cash
-37.9%
£520,000 £323,000
-
Net assets
-99.9%
£34,128,000 £23,000
-
Employees
-58.8%
85 35
-
Operating profit
-25.7%
£5,756,000 £4,278,000
-
Profit before tax
+4%
£5,447,000 £5,664,000
-
Wages
-54.7%
£3,322,000 £1,506,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers